Moderna beat first-quarter expectations Thursday. The news could bolster Moderna stock which is approaching its first ...
All vaccines have at least occasional side effects. But people who say they were injured by COVID vaccines believe their cases have been ignored.
Pfizer (NYSE: PFE) on Friday announced the FDA's approval of its one-time gene therapy, called Beqvez, for the rare genetic bleeding disorder hemophilia B. It marks the large pharmaceutical ...
and Seagen - received the FDA's accelerated approval for the same indication in 2021. It was added to Pfizer's oncology portfolio last year through a $43 billion deal to acquire Seagen ...
Pfizer's huge facility in North Carolina produces its first FDA-approved gene therapy, which runs $3.5 million a dose. The U.S. Food and Drug Administration has approved a gene therapy developed ...
to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy. The nAbCyte cell-based neutralizing ...
(Adds details on the approval, background and other details from paragraph 2) April 29 (Reuters) - The U.S. Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating ...
The Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating cervical cancer patients whose disease had progressed on or after chemotherapy, the agency said on Monday.
The U.S. Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating cervical cancer patients whose disease had progressed on or after chemotherapy, the agency said on ...
Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S. On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with moderate-to ...
The FDA's full approval covers Tivdak in the treatment of recurrent or metastatic cervical cancer. Danish biotechnology company Genmab and Pfizer-owned Seagen codeveloped Tivdak under a cost- and ...
The FDA's full approval covers Tivdak in the treatment of recurrent or metastatic cervical cancer. Danish biotechnology company Genmab and Pfizer-owned Seagen codeveloped Tivdak under a cost- and ...